Omicron新變種病毒株已蔓延至多國 本港疫苗股隨外圍逆市造好 康希諾曾漲13%
南非出現較Delta傳播力更快及對現有疫苗有抵抗力的已被世衛命名爲Omicron的新變種病毒株,並已蔓延至英國、德國、意大利、荷蘭、本港、以色列、英國及澳洲等國,觸發市場恐慌,環球股市上週五全面急挫。反觀,疫苗股受捧,其中輝端(PFE.US)上週五股價漲逾6%高見54.94美元再創紀錄高,BioNTech(BNTX.US)及莫德納(MRNA.US)分別急漲逾14%及近21%。
於本港上市的疫苗股今天全面逆恆指(現報23,888,反覆續跌0.8%)造好,尤其是開拓藥業-B(09939.HK)承上週五逆市倒升8.6%勢,今早曾進一步升破10天及百天線(58.7元及61.05元),最高見64元,現報59.35元,續升3.6%;康希諾生物-B(06185.HK)據報已開始針對Omicron變異病毒株開展疫苗研發,股價曾急彈近13%高見172.8元,現報160.5元,回升4.7%。
本月5日才以每股13.38元上市的三葉草生物-B(02197.HK)高見12.42元,現報12.36元,回升4.9%。
復星醫藥(02196.HK)重越10天線(39.97元),最高見42.7元,現報40.4元,回升2.7%。騰盛博藥-B(02137.HK)五連升,最高見46.45元,現報44.5元,續升1.5%。
藍籌藥明生物(02269.HK)曾重越20天及10天線(105.8元及106.9元),最高見110.5元,現報105.8元,升2.3%;藥明康德(02359.HK)四連升,最高見176.7元,現報172元,續升2.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.